Elizabeth M. Jaffee and Antoni Ribas will look to feature the next wave of immuno-oncology advances as Cancer Immunology Research's...
At a recent AACR Special Conference, experts discussed emerging therapeutic options to overcome resistance to Bacillus Calmette-Guérin (BCG).
Researchers at the AACR Annual Meeting 2024 shared how AACR Project GENIE data is helping their studies.
A recap of the plenary sessions, cutting-edge science, clinical trials, and more covered by the AACR blog.
Researchers around the world are designing and implementing methods to increase access to cancer care in low-resource areas.
During his Presidential Address at the AACR Annual Meeting 2024, Philip D. Greenberg discussed research driving immunotherapy forward.
Learn about synthetic lethality and approved drugs that use this approach to treat cancer.
Dr. Alan D’Andrea spoke about a new grant looking for fresh perspectives in Fanconi anemia-related cancer research.
The closing plenary of the AACR Annual Meeting 2024 recapped basic science, prevention, clinical advances, and more.
The journey to the first approved TIL therapy began with Steven A. Rosenberg over 30 years ago.
The editors of AACR's journals highlight studies from May, including machine learning, savings from quitting smoking, and more.